Nanjing Delova has cleared a major clinical hurdle in postoperative pain management. Two pivotal Phase 3 trials show QP-6211 delivered superior pain control and sharply reduced opioid use versus both standard ropivacaine and placebo.
An NDA has now been submitted.
Why QP-6211 Matters?
Postoperative pain remains a key driver of opioid exposure.
QP-6211 is designed to change that.
Key differentiators:
- Long-acting, extended-release ropivacaine
- Sustained analgesia through the critical 72-hour postoperative window
- Consistent efficacy across different surgical models
- Non-opioid, local infiltration approach
Delova positions QP-6211 as a next-generation, best-in-class local anesthetic.
Phase 3 Trial Overview
Delova conducted two randomized, double-blind, placebo- and active-controlled Phase 3 trials in China.
Surgical models:
- Hemorrhoidectomy (n=309)
- Bunionectomy (n=185)
Comparator arms included:
- Ropivacaine hydrochloride injection
- Placebo
Hemorrhoidectomy: Strong Pain and Opioid Reduction
QP-6211 met the primary and all key secondary endpoints. Key outcomes versus placebo:
- 58% reduction in pain (AUC₀–₇₂h NRS)
- 55% reduction in late pain (AUC₄₈–₇₂h)
- 88% reduction in opioid consumption
- 83% of patients required no opioids
All results were statistically significant (p < 0.0001). QP-6211 also outperformed standard ropivacaine across all endpoints.
Bunionectomy: Consistent Efficacy Confirmed
Results closely mirrored the hemorrhoidectomy study.
Key outcomes versus placebo:
- 49% reduction in pain (AUC₀–₇₂h)
- 51% reduction in late pain (AUC₄₈–₇₂h)
- 74% reduction in opioid use
- 75% of patients avoided opioids entirely
Again, all comparisons were statistically significant.
Safety Profile
QP-6211 was generally well tolerated across both trials.
Key safety observations:
- Mostly mild to moderate adverse events
- No treatment-related serious adverse events
- Overall AE rates comparable to placebo
In the bunionectomy study, AE incidence was lower than placebo.
Technology Behind QP-6211
QP-6211 is built on Delova’s proprietary Cryslova™ platform.
Platform advantages:
- Oil-free, aqueous injectable suspension
- Continuous, uniform drug release for at least five days
- Predictable pharmacokinetics across procedures
Ropivacaine itself offers a higher cardiotoxicity safety margin than bupivacaine, with better sensory selectivity.
What Comes Next?
With two positive Phase 3 trials completed, Delova has:
- Submitted an NDA for QP-6211
- Positioned the asset as a non-opioid alternative for postoperative pain
- Expanded its long-acting analgesic portfolio beyond QAMZOVA®
If approved, QP-6211 could materially reduce opioid exposure after surgery—without sacrificing pain control.
